ABC‐DLBCL is associated with constitutive activation of the nuclear factor kappa B (NF‐κB) pathway [4] that leads to chemotherapy resistance and inferior clinical outcomes. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.